Cavedo, Enrica
Grothe, Michel J.
Colliot, Olivier
Lista, Simone
Chupin, Marie
Dormont, Didier
Houot, Marion
Lehéricy, Stephane
Teipel, Stefan
Dubois, Bruno
Hampel, Harald
Croisile, Bernard
Louis Tisserand, Guy
Bonafe, Alain
Ousset, Pierre J
Rouaud, Olivier
Ricolfi, Fréderic
Vighetto, Alain
Pasquier, Florence
Delmaire, Christine
Ceccaldi, Mathieu
Girard, Nadine
Duveau, Françoise
Sarazin, Marie
,
Article History
Received: 5 April 2017
Accepted: 31 July 2017
First Online: 15 September 2017
Competing Interests
: The clinical trial with Donepezil leading to the analysed dataset was supported by Eisai SAS France. Eisai SAS France supported for data collection and for the investigation of the primary endpoint of the study. Dr Cavedo, Dr Grothe, Dr Chupin, Dr Teipel and Dr Dormont declare no competing financial interests related to the present article. Dr Dubois has received consulting fees from Eli Lilly, Dr Dubois have received Grant support from Pfizer in 2012; Dr Colliot declares no competing financial interests related to the present article, Dr Colliot he has received consulting fees from Guerbet and lecture fees from Lundbeck and Roche. Dr Lista has received lecture fees from Roche. Dr Hampel, Dr Cavedo and Dr Lista are supported by the AXA Research Fund, the Université Pierre et Marie Curie and the “Association pour la Recherche sur Alzheimer”, Paris, France. Dr Hampel declares no competing financial interests related to the present article. During the last 36 months Dr Hampel has received lecture honoraria and/or research grants (paid to the institution) and/or travel funding and/or participated in scientific advisory boards and/or as a consultant to diagnostic, biotechnology and pharmaceutical companies involved in the manufacture and marketing of biomarkers and/or diagnostics and/or drugs or medicinal products for cognitive impairment and Alzheimer’s disease including Roche Pharmaceuticals and Diagnostics, GE Healthcare, Avid, Eli Lilly and Company, GlaxoSmithKline-Biologicals, Jung-Diagnostics, Cytox, Anavex, Axovant, Biogen Idec, Oryzon Genomics. He is co-inventor in patents relating to biological markers and/or diagnostics and has not received any royalties.